CD40-B induce anti-neuroblastoma T cells from pediatric oncology patients. (A) PBMCs from patients with neuroblastoma were stimulated twice with CD40-B electroporated with pooled tumor RNA from 3 neuroblastoma cell lines (left and right panels) or GFP RNA(middle panel) and were assayed in chromium release assays against neuroblastoma cell lines (• SK-NRA, HLA-A2⁺; ▪ CHLA-90, HLA-A2⁺; ○ SK-NAS, HLA-A2^–; ▵ SH-SY5Y, HLA-class I^–); ⋄ autologous PHA blasts; autologous CD34⁺ stem cells. PBMCs were obtained after induction chemotherapy (left and middle panels) or 90 days after stem cell transplantation (right panel). Similar results were obtained with 2 donors, except for experiments using PHA blasts or stem cells, which were performed once. (B) Autologous PBMCs from a patient with neuroblastoma were stimulated twice with CD40-B electroporated with autologous tumor RNA (left panel), GFP RNA (middle panel), or autologous lymphocyte RNA (right panel) and were assayed in chromium release assays against neuroblastoma cell lines. Symbols are the same as in panel A. (C) Cultures stimulated with GFP RNA (left column), pooled neuroblastoma cell line RNA (middle column), or autologous tumor RNA (right column) were labeled with anti-CD8, anti-CD14, anti-CD4, and HLA-A2/survivin or HLA-A2/tax tetramers and were analyzed as in Figure 2.